Onconetix, Inc.

Onconetix, Inc. reported a net loss of $2.87 million for Q2 2026 and $7.08 million for the six months ended June 30, 2026. The company's cash balance was $5.94 million as of June 30, 2026, and it incurred significant goodwill impairment losses. Management raised substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and the need for additional financing, despite recent Series F Preferred Stock proceeds.

Onconetix filed an S-1 registration statement for the resale of up to 100,000,000 shares of common stock by selling stockholders, primarily from a July 2026 Series F private placement. The company also detailed a Share Exchange Agreement to acquire Realbotix LLC, where the seller could own 75-90% of Onconetix's fully diluted shares post-closing, contingent on Net Cash between $12.5M and $20M. Onconetix secured a new $750M equity line of credit and raised $30.2M in Series F financing, with $30M of the commitment fee satisfied by the PIPE investor's Series F investment. The company continues to face substantial doubt about its ability to continue as a going concern, with a cash balance of $5.4M as of August 10, 2026.

Onconetix, Inc. announced that Realbotix LLC, its pending acquisition target, has secured an agreement with a recognized streaming platform. This deal will feature one of Realbotix's humanoid robots as a character in an upcoming episode of a popular Emmy-awarded television series. This expands Realbotix's market reach into the entertainment industry, complementing its existing presence in education, healthcare, hospitality, and customer engagement. The acquisition of Realbotix LLC by Onconetix is an all-stock transaction, anticipated to close in the second half of 2026, pending shareholder and regulatory approvals.

Onconetix, Inc. announced that its Swiss subsidiary, Proteomedix AG, has appointed Ralph Schiess, PhD, to its Board of Directors. Dr. Schiess is a co-founder of Proteomedix and co-developer of Proclarix®, Onconetix's prostate cancer diagnostic blood test, bringing extensive scientific and commercial expertise. Additionally, Thomas Meier, PhD, was re-elected as Chairman of the Board for an additional one-year term at the Annual General Meeting.

Onconetix, Inc. entered into a Securities Purchase Agreement with an accredited investor for a Private Investment in Public Equity (PIPE) financing. The company will issue 37,812 shares of Series F convertible preferred stock for an aggregate purchase price of $30,249,600. Concurrently, a Registration Rights Agreement was executed, obligating Onconetix to register the common stock underlying the Series F Preferred Stock for resale. The Series F Preferred Stock has a stated value of $1,000 per share and an initial conversion price of $0.9767 per common share.

Onconetix, Inc. provided an update on Realbotix LLC, its pending acquisition target. Realbotix announced a partnership with Bloom Procurement Services to launch a pilot program deploying socially assistive humanoid robots in UK care settings to combat loneliness and improve wellbeing among older adults. Realbotix has also been accredited as a supplier on Bloom’s public sector marketplace. The acquisition of Realbotix LLC by Onconetix is an all-stock transaction, anticipated to close in the second half of 2026, subject to shareholder and regulatory approvals.

Onconetix, Inc. provided an update regarding its pending acquisition target, Realbotix LLC. Realbotix has launched a pilot program at Salamanca City Central School District, deploying its AI-powered teacher's assistant, Optio, and an M-Series humanoid robot. The program is set to expand to approximately 500 high school students by Fall 2026. Onconetix previously announced its definitive agreement to acquire Realbotix LLC in an all-stock transaction, with closing anticipated in the second half of 2026, subject to shareholder and regulatory approvals.

Onconetix, Inc. announced a 1-for-10 reverse stock split of its common stock, effective 12:01 a.m. Eastern Time on May 21, 2026. The Board of Directors fixed the ratio on May 8, 2026, following stockholder approval on April 30, 2026. This action is primarily intended to bring the company into compliance with Nasdaq's minimum bid price requirement. Trading on a split-adjusted basis will commence on May 21, 2026, under a new CUSIP number.

Onconetix, Inc. announced that its Board of Directors has approved a 1-for-10 reverse stock split of its common stock, effective May 21, 2026. This action, previously approved by stockholders, is intended to help the company maintain compliance with The Nasdaq Capital Market's minimum bid price requirement. Following the split, the number of outstanding shares will be reduced from approximately 11.4 million to 1.14 million, with fractional shares being compensated in cash.

Onconetix, Inc. announced Q1 2026 operational and clinical progress for its Swiss subsidiary, Proteomedix AG, developer of the Proclarix® diagnostic blood test. The update highlighted two new peer-reviewed publications reinforcing Proclarix's performance and prognostic value. Additionally, Proteomedix initiated the multi-center PRIME study with Labcorp Holdings Inc. in the U.S. to evaluate Proclarix, alongside continued European commercial expansion.